title: Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
abstract: Tumor overexpression of urokinase-type plasminogen activator (uPA) and its specific inhibitor SerpinE1 (plasminogen activator inhibitor type-1) correlates with poor prognosis and increased metastatic potential. Conversely, tumor expression of uPA and another specific inhibitor, SerpinB2 (plasminogen activator inhibitor type-2), are associated with favorable outcome and relapse-free survival. It is not known how overexpression of these uPA inhibitors results in such disparate outcomes. A possible explanation may be related to the presence of a proposed low density lipoprotein receptor (LDLR)-binding motif in SerpinE1 responsible for mitogenic signaling via ERK that is absent in SerpinB2. We now show that complementation of such a LDLR-binding motif in SerpinB2 by mutagenesis of two key residues enabled high affinity binding to very LDLR (VLDLR). Furthermore, the VLDLR-binding SerpinB2 form behaved in a manner indistinguishable from SerpinE1 in terms of enhanced uPA-SerpinB2 complex endocytosis and subsequent ERK phosphorylation and cell proliferation; that is, the introduction of the LDLR-binding motif to SerpinB2 was necessary and sufficient to allow it to acquire characteristics of SerpinE1 associated with malignancy. In conclusion, this study defines the structural elements underlying the distinct interactions of SerpinE1 versus SerpinB2 with endocytic receptors and how differential VLDLR binding impacts on downstream cellular behavior. This has clear relevance to understanding the paradoxical disease outcomes associated with overexpression of these serpins in cancer.
authors: School of Biological Sciences, University of Wollongong, Wollongong, New South Wales 2522, Australia.
authors: Blake J
authors: BJ
authors: Cochran
authors: David R
authors: DR
authors: Croucher
authors: Sergei
authors: S
authors: Lobov
authors: Darren N
authors: DN
authors: Saunders
authors: Marie
authors: M
authors: Ranson
references: Biochem J. 2007 Dec 1;408(2):203-10
references: 17696882
references: J Clin Oncol. 2007 Nov 20;25(33):5287-312
references: 17954709
references: J Biol Chem. 1998 Mar 13;273(11):6358-66
references: 9497365
references: J Biol Chem. 1992 Jun 5;267(16):11606-11
references: 1375944
references: Front Biosci (Landmark Ed). 2009 Jan 01;14:4575-87
references: 19273372
references: J Biol Chem. 1995 Nov 3;270(44):26550-7
references: 7592875
references: BMC Biotechnol. 2009 May 14;9:43
references: 19442270
references: FEBS Lett. 2010 Aug 4;584(15):3469-73
references: 20624392
references: Nat Rev Cancer. 2005 Aug;5(8):591-602
references: 16056258
references: J Biol Chem. 1990 Jun 15;265(17):9904-8
references: 2161846
references: J Urol. 2005 Aug;174(2):461-5
references: 16006865
references: Trends Endocrinol Metab. 2002 Mar;13(2):66-74
references: 11854021
references: J Mol Biol. 2005 Nov 11;353(5):1069-80
references: 16214170
references: Thromb Haemost. 1998 Nov;80(5):822-8
references: 9843178
references: Nat Rev Cancer. 2008 Jul;8(7):535-45
references: 18548086
references: Cancer Res. 2000 Feb 1;60(3):636-43
references: 10676647
references: FEBS Lett. 2002 Jun 19;521(1-3):91-4
references: 12067733
references: Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S46-58
references: 14600592
references: Exp Cell Res. 2004 Jul 1;297(1):259-71
references: 15194441
references: J Biol Chem. 1994 Sep 16;269(37):23268-73
references: 8083232
references: FEBS J. 2006 Nov;273(22):5143-59
references: 17042782
references: Curr Pharm Des. 2003;9(19):1545-64
references: 12871067
references: J Thromb Haemost. 2003 Jul;1(7):1663-70
references: 12871303
references: J Mol Biol. 2006 Sep 29;362(4):700-16
references: 16938309
references: Biochem J. 1998 Jan 1;329 ( Pt 1):55-63
references: 9405275
references: Br J Haematol. 1999 Jun;105(4):920-7
references: 10554801
references: Curr Pharm Des. 2004;10(1):39-49
references: 14754404
references: J Surg Oncol. 1999 Jun;71(2):130-5
references: 10389872
references: Nat Struct Biol. 1995 Oct;2(10):891-7
references: 7552714
references: Curr Opin Cell Biol. 2000 Oct;12(5):621-8
references: 10978899
references: Eur J Biochem. 1993 Dec 15;218(3):1071-82
references: 7506655
references: J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
references: 11792750
references: J Biol Chem. 1996 May 31;271(22):12716-23
references: 8662688
references: J Clin Oncol. 1999 Oct;17(10):3048-57
references: 10506599
references: J Biol Chem. 2006 Apr 14;281(15):10206-13
references: 16459332
references: J Cell Biol. 2001 Feb 19;152(4):741-52
references: 11266465
references: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64
references: 11818541
references: J Biol Chem. 2004 May 21;279(21):22595-604
references: 15001579